Market Place
Sourcing Support
Apogee Doses 1st Patient in Ph 2 APEX Trial for Atopic Dermatitis
03 Feb 2025 //
GLOBENEWSWIRE
Apogee to Participate at Guggenheim SMID Cap Biotech Conference
29 Jan 2025 //
GLOBENEWSWIRE
Apogee Doses 1st Participants In APG333 Ph 1 Trial For Respiratory
10 Dec 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Announces Agenda for Virtual R&D Day
29 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Host Inaugural Virtual R&D Day on Dec 2
18 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Q3 2024 Financial Results & Progress
12 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Nov Investor Conferences
04 Nov 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Announces Phase 1 Trial Results For APG777
24 Oct 2024 //
GLOBENEWSWIRE
Apogee Announces Presentation at the ACAAI Annual Scientific Meeting
16 Oct 2024 //
GLOBENEWSWIRE
Apogee Therapeutics To Attend Stifel Immunology And Inflammation Summit
12 Sep 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Appoints Jeff S. Hartness as CCO
09 Sep 2024 //
GLOBENEWSWIRE
Apogee Doses First Participants In APG990 Phase 1 Trial For Atopic Dermatitis
19 Aug 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Q2 2024 Results And Pipeline Progress
12 Aug 2024 //
GLOBENEWSWIRE
Apogee Therapeutics: Lisa Bollinger Joins Board Of Directors
28 May 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming June Investor Conferences
23 May 2024 //
GLOBENEWSWIRE
Apogee Doses First Patient In APG777 Phase 2 Atopic Dermatitis Trial
15 May 2024 //
GLOBENEWSWIRE
Apogee Highlights Pipeline, Reports Q1 2024 Results
13 May 2024 //
GLOBENEWSWIRE
Apogee To Participate In BofA Healthcare Conference 2024
06 May 2024 //
GLOBENEWSWIRE
Apogee, Spyre founder launches its third biotech and heads straight to Nasdaq
03 Apr 2024 //
ENDPTS
Apogee Therapeutics Announces First Participants Dosed in Ph1 Trial of APG808
25 Mar 2024 //
GLOBENEWSWIRE
Apogee Therapeutics, Inc. Announces Closing of Upsized Public Offering
12 Mar 2024 //
GLOBENEWSWIRE
Apogee Announces Pricing of Upsized $420 Million Underwritten Public Offering
07 Mar 2024 //
PRESS RELEASE
Apogee Catapults 42% After Eczema Drug Blows Expectations Out Of The Water
06 Mar 2024 //
YAHOO FINANCE
Apogee Announces Positive Results from Ph 1 Healthy Volunteer Trial for APG777
05 Mar 2024 //
GLOBENEWSWIRE
Apogee Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
05 Mar 2024 //
GLOBENEWSWIRE
Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering
05 Mar 2024 //
GLOBENEWSWIRE
Apogee to Report Interim Results from Phase 1 Healthy Volunteer Trial for APG777
04 Mar 2024 //
GLOBENEWSWIRE
Apogee Therapeutics to Present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
GLOBENEWSWIRE
Apogee Reports Third Quarter 2023 Financial Results
13 Nov 2023 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming November Investor Conferences
30 Oct 2023 //
GLOBENEWSWIRE
Apogee Announces Two Abstracts Accepted for Presentation at the EADV Congress
27 Sep 2023 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate at the 2023 Stifel Virtual I&I Day
14 Sep 2023 //
GLOBENEWSWIRE
Apogee Highlights Corporate Progress and Reports 2Q 2023 FYR
28 Aug 2023 //
GLOBENEWSWIRE
Apogee Appoints Mark C. McKenna as Chairman of its Board
21 Aug 2023 //
GLOBENEWSWIRE
Apogee Announces First Participants Dosed Ahead of Schedule in Phase 1 of APG777
07 Aug 2023 //
GLOBENEWSWIRE
Apogee Therapeutics to Participate in Upcoming August Investor Conferences
02 Aug 2023 //
GLOBENEWSWIRE
Apogee Therapeutics, Inc. Announces Closing of Upsized Initial Public Offering
18 Jul 2023 //
GLOBENEWSWIRE
Apogee and Sagimet help crack open a stuck window on Wall Street
13 Jul 2023 //
ENDPTS
Apogee Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering
13 Jul 2023 //
GLOBENEWSWIRE
Apogee and Sagimet’s IPO plans come into view, with targeted raises of $228M
10 Jul 2023 //
ENDPTS
